We would love to hear your thoughts about our site and services, please take our survey here.
Yes sorry typo it’s ballroom 20 ! Yes it is huge , not just the room . It’s the news on the trial and explanation of how much Avidimab will impact and improve patients lives
A 15 minute captive audience on the hot subject of . Cancer vaccines being ready for PRIME TIME !
I found this interesting . the presentation in Ballroom 50 a large room with lots of seating ? :
Presentation and Session Format. Speakers in regular Minisymposia and Clinical Trials Minisymposia have 10 minutes to present their talks and five minutes to answer questions.
Advance Preparation with Session Chairpersons.
[Note: These instructions and deadlines apply to presenters in regular Minisymposia. Presenters in Clinical Trials Minisymposia have a later deadline for slide upload and should refer to their e-mail notification for instructions.]
so updated slides and 5 minutes answering questions at roughly midnight ? would love to know what questions will be asked ? especially the answers ?
Looking forward to 7 am tomorrow ?
I agree C11 just wonder if a deal will be delayed until then because of FOMO .
After all the deputy chair of the AACR 24 said the session was one she was looking forward to
Cancer vaccine Prime Time ?
for now or Blockbuster with improved addition of avidimab which will catch attention I am sure . Used ingenious move in covidity to prove safe . I may be wrong however please correct me
Find updates link with profiles of speakers along with Lindy Durrant
https://www.abstractsonline.com/pp8/#!/20272/session/663
And on page 44 vaccines ready for prime time planner
https://www.aacr.org/wp-content/uploads/2024/04/AACR2024_Program_Guide.pdf
Cancer Vaccines: Ready for Prime Time?
Cochairs: Ecaterina Elena Dumbrava, Houston, TX;
https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html
Ulka N. Vaishampayan, Ann Arbor MI
https://www.uofmhealth.org/profile/33465/ulka-vaishampayan-mbbs
Introduction. Ecaterina Elena Dumbrava, Houston, TX
1. https://faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html
CT021 Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC. Willemijn Theelen, Amsterdam, Netherlands
https://www.avl.nl/en/specialists-employees/specialists/pulmonologists/willemijn-theelen/
CT022 Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study . Saurav D. Haldar, Baltimore, MD
https://health.usnews.com/doctors/saurav-haldar-1192938
CT023 Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Making a cold tumor hot. Sujit S. Nair, New York, NY
https://icahn.mssm.edu/about/departments/urology/research/prostate-cancer
CT024 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial. Lindy Durrant, Oxford, United Kingdom
https://www.theguardian.com/business/2023/jun/20/designing-a-vaccine-that-covers-all-cancers-is-hard-biotech-pioneer-lindy-durrant
CT134 Safety and immunologic impact of neoadjuvant/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4 in pancreatic adenocarcinoma. Arielle Urman, Baltimore, MD
https://health.usnews.com/doctors/arielle-urman-1812281
CT025 Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer. Vinod P. Balachandran, New York, NY
https://health.usnews.com/doctors/vinod-balachandran-118798
CT026 Systemic responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). Charles J. Link, Wynnewood, PA
Closing remarks. Ulka N. Vaishampayan,
https://www.uofmhealth.org/profile/33465/ulka-vaishampayan-mbbs
Https://www.abstractsonline.com/pp8/#!/20272/session/663
And on page 44 vaccines ready for prime time planner
https://www.aacr.org/wp-content/uploads/2024/04/AACR2024_Program_Guide.pdf
Cancer Vaccines: Ready for Prime Time?
Cochairs: Ecaterina Elena Dumbrava, Houston, TX; Ulka N. Vaishampayan, Ann Arbor, MI Introduction. Ecaterina Elena Dumbrava, Houston, TX
CT021 Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC. Willemijn Theelen, Amsterdam, Netherlands
CT022 Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study . Saurav D. Haldar, Baltimore, MD
CT023 Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Making a cold tumor hot. Sujit S. Nair, New York, NY
CT024 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial. Lindy Durrant, Oxford, United Kingdom
CT134 Safety and immunologic impact of neoadjuvant/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4 in pancreatic adenocarcinoma. Arielle Urman, Baltimore, MD
CT025 Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer. Vinod P. Balachandran, New York, NY
CT026 Systemic responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). Charles J. Link, Wynnewood, PA
Closing remarks. Ulka N. Vaishampayan, Ann Arbor, MI
Morning TF Thinking around on the embargo policy along with what the co chair said
In my post from yesterday morning s post 8.19 am tiltle , which I suggest you read in full
“1 door closes world vaccine congress another opens ACCR 2024 I”
This article came out at the end of the world vaccine congress which finished yesterday https://www.fiercebiotech.com/biotech/were-open-business-fdas-peter-marks-says-agency-ready-review-novel-cancer-vaccines-despite
( ray pointer reposted the article , however I feel both of the articles should be read together )
Peter marks he FDA's vaccine czar Peter Marks, M.D., Ph.D., is weighing new regulatory questions surrounding the products.( Vaccines )
“As new cancer vaccines—led by Moderna and Merck’s mRNA-4157—near pivotal trial readouts, the FDA’s vaccines czar Peter Marks, M.D., Ph.D., said the agency is ready to review the shots despite AI-related unknowns.
“We are ready to review—we’re open for business,” Marks, director of the FDA’s Center for Biologics Evaluation and Research, said of cancer vaccines at the 2024 World Vaccine Congress (WVC).”
“We have therapeutic cancer vaccines coming in; I think we would review them very much like we could review potentially a CAR-T cell or other therapeutic products,” Marks said.
I included 2 lines
NOW THE ACCR kicks off today . Suggest you
what AACR Co chair Cristina Curtis is most looking forward to
"I am excited about is around cancer vaccines and whether they are really ready for prime time."
https://www.genengnews.com/topics/cancer/aacr-co-chair-christina-curtis-shares-themes-and-highlights-from-the-meeting/
Therefore maybe a little more patience is required if the following applies from my 11 am post in relation to lEmbargoes
could be 1,2 or 3
* Late-breaking and clinical trials abstract text release on April 5, 2024 at 12 p.m. PT/3 p.m. ET
* Abstracts selected for the official AACR Annual Meeting Press Program will lift embargo at the time of the related press conference or presentation at the meeting
“Any information beyond what is in the abstract is embargoed until the beginning of the session where the study is being presented.”
Just in the nick of time to be tucked away in an isa
Rns 3rd April
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that certain employees of the Company have exercised their options over 160,000 ordinary shares in the Company.
An application has been made to London Stock Exchange plc for these shares to be admitted to trading on AIM and it is expected that this will become effective at 8.00 a.m. on 4 April 2024.
RNS 2nd of April
Title: A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial
Session: CTMS01 - Cancer Vaccines: Ready for Prime Time?
Session Date and Time: Sunday 7 April 2024, 3:50 PM - 4:00 PM PST
Location: Ballroom 20 AB - Upper Level - Convention Center
Published Abstract Number: CT024
Speaker: Professor Lindy Durrant, Chief Executive Officer and Chief Scientific Officer
Authors: H. Shaw, P. Patel, M. Payne, S. Kumar, M. Highley, K. Prasad, R. Board, C. Barlow, S.
EMBARGO POLICY
Please read the following information closely regarding the embargo policy for the AACR Annual Meeting 2024. You may contact Julia Gunther at julia.gunther@aacr.org with additional questions.
IMPORTANT DATES AND TIMES
Abstracts will be posted to the online itinerary planner at the time embargoes lift. The dates and times when embargoes lift are:
* Regular abstract titles and text release on March 5, 2024 at 4:30 p.m. ET
* Late-breaking and clinical trials abstract titles ONLY (no text) release on March 5, 2024 at 4:30 p.m. ET
* Late-breaking and clinical trials abstract text release on April 5, 2024 at 12 p.m. PT/3 p.m. ET
* Abstracts selected for the official AACR Annual Meeting Press Program will lift embargo at the time of the related press conference or presentation at the meeting
OUTSIDE PRESS RELEASES
Public information officers or public relations firms representing academia or industry with abstracts in the meeting can issue press releases on information that is publicly available via the AACR’s online itinerary planner. Any information beyond what is in the abstract is embargoed until the beginning of the session where the study is being presented.
Institutions or companies planning to promote abstracts that are selected for the official AACR Annual Meeting Press Program must contact Julia Gunther at julia.gunther@aacr.org to ensure all embargo policies are followed.
EMBARGO VIOLATIONS: PRESENTERS AND PUBLIC RELATIONS
Presenters, their companies/institutions, and affiliated public relations representatives who break the AACR’s embargo policy as outlined above could jeopardize an abstract’s placement in the scientific program and press events.
EMBARGO VIOLATIONS: MEDIA
Individuals registered as press for the AACR Annual Meeting 2024 agree to abide by all embargoes. In advanc
RNS on trial data . I would say Monday after the presentation ? vote yes or no
Just in the nick of time to be tucked away in an isa
Rns 3rd April
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that certain employees of the Company have exercised their options over 160,000 ordinary shares in the Company.
An application has been made to London Stock Exchange plc for these shares to be admitted to trading on AIM and it is expected that this will become effective at 8.00 a.m. on 4 April 2024.
RNS 2nd of April
Title: A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial
Session: CTMS01 - Cancer Vaccines: Ready for Prime Time?
Session Date and Time: Sunday 7 April 2024, 3:50 PM - 4:00 PM PST
Location: Ballroom 20 AB - Upper Level - Convention Center
Published Abstract Number: CT024
Speaker: Professor Lindy Durrant, Chief Executive Officer and Chief Scientific Officer
Authors: H. Shaw, P. Patel, M. Payne, S. Kumar, M. Highley, K. Prasad, R. Board, C. Barlow, S.
EMBARGO POLICY
Please read the following information closely regarding the embargo policy for the AACR Annual Meeting 2024. You may contact Julia Gunther at julia.gunther@aacr.org with additional questions.
IMPORTANT DATES AND TIMES
Abstracts will be posted to the online itinerary planner at the time embargoes lift. The dates and times when embargoes lift are:
* Regular abstract titles and text release on March 5, 2024 at 4:30 p.m. ET
* Late-breaking and clinical trials abstract titles ONLY (no text) release on March 5, 2024 at 4:30 p.m. ET
* Late-breaking and clinical trials abstract text release on April 5, 2024 at 12 p.m. PT/3 p.m. ET
* Abstracts selected for the official AACR Annual Meeting Press Program will lift embargo at the time of the related press conference or presentation at the meeting
OUTSIDE PRESS RELEASES
Public information officers or public relations firms representing academia or industry with abstracts in the meeting can issue press releases on information that is publicly available via the AACR’s online itinerary planner. Any information beyond what is in the abstract is embargoed until the beginning of the session where the study is being presented.
Institutions or companies planning to promote abstracts that are selected for the official AACR Annual Meeting Press Program must contact Julia Gunther at julia.gunther@aacr.org to ensure all embargo policies are followed.
EMBARGO VIOLATIONS: PRESENTERS AND PUBLIC RELATIONS
Presenters, their companies/institutions, and affiliated public relations representatives who break the AACR’s embargo policy as outlined above could jeopardize an abstract’s placement in the scientific program and press events.
EMBARGO VIOLATIONS: MEDIA
Individuals registered as
See my post today from Cristina Curtis Co chair of AACr on what she is looking forward to this year .. Vaccines ready for PRIME TIME .
"Another mini-symposium that I am excited about is around cancer vaccines and whether they are really ready for prime time . Obviously, this is a very hot topic which has gained a lot of traction following COVID and the changes in how we think about vaccines."
see my earlier post to read full articles
Good morning I have read these 2 articles
1. What FDA's head said yesterday on Novel cancer vaccines
https://www.fiercebiotech.com/biotech/were-open-business-fdas-peter-marks-says-agency-ready-review-novel-cancer-vaccines-despite
As new cancer vaccines—led by Moderna and Merck’s mRNA-4157—near pivotal trial readouts, the FDA’s vaccines czar Peter Marks, M.D., Ph.D., said the agency is ready to review the shots despite AI-related unknowns.
“We are ready to review—we’re open for business,” Marks, director of the FDA’s Center for Biologics Evaluation and Research, said of cancer vaccines at the 2024 World Vaccine Congress (WVC).
“We have therapeutic cancer vaccines coming in; I think we would review them very much like we could review potentially a CAR-T cell or other therapeutic products,” Marks said.
2. what AACR Co chair Cristina Curtis is most looking forward to
"I am excited about is around cancer vaccines and whether they are really ready for prime time."
https://www.genengnews.com/topics/cancer/aacr-co-chair-christina-curtis-shares-themes-and-highlights-from-the-meeting/
The American Association for Cancer Research (AACR) meeting kicks off this weekend, in San Diego, California. The event is a whirlwind of sessions, keynotes, mini-symposia, posters and exhibitors. How does it all come together? A village of people including AACR program staff, the AACR board of directors, a program committee, and two meeting co-chairs who work together to make it all happen.
The week before the conference, GEN sat down with one of the co-chairs of the meeting, Christina Curtis, PhD, a professor of medicine, genetics and biomedical data science at Stanford University where she also serves as the director of artificial intelligence and cancer genomics and of breast cancer translational research.
Another mini-symposium that I am excited about is around cancer vaccines and whether they are really ready for prime time. Obviously, this is a very hot topic which has gained a lot of traction following COVID and the changes in how we think about vaccines.
Yes Burble would appear not to be a closed period , just to clarify . does RNS mean they have bought shares and are now going to sell them on the open Aim market ? I am a little confused
did anyone see this this yesterday ?
https://klse1.i3investor.com/blogs/future_tech/2024-04-02-story-h-184723070-Redx_to_quit_London_Stock_Exchange_s_AIM_citing_low_liquidity.jsp
Biotech company Redx Pharma Plc is set to pull its shares from the London Stock Exchange’s smallest market, citing liquidity constraints and saying it will attract investors more easily as a private company.
The decision is another blow to the LSE as innovative biotechs increasingly look to the US. Companies including Barinthus Biotherapeutics, Zura Bio and OKYO Pharma have opted to sell shares in New York or move their listings there.
London’s Alternative Investment Market, or AIM, is designed to help smaller companies access capital. But Redx’s board concluded that “our current market valuation is not reflective of our track record or future potential and is not conducive to raising the level of capital required for our growing clinical portfolio”.
Redx develops small-molecule medicines targeting cancer and diseases associated with fibrosis. Its lead product is in mid-stage clinical trials.
Britain has faced difficult questions in recent years regarding its attractiveness as a place for life-sciences companies to grow, with increasing concern that biotech companies may choose to list in the US rather than in London.
In February, Redx denied a report by The Times that it was considering switching its listing to New York.
Jane Griffiths, who chairs Redx’s board, attempted to allay concerns that the move to delist was a reflection on Britain. The company, she said, believes that the UK “is an excellent hub for scientific discovery and drug development”. Redx will retain its headquarters at Alderley Park in Cheshire.
The decision to re-register as a private company will be subject to shareholder approval at a meeting on April 19.
The full press release
https://www.redxpharma.com/wp-content/uploads/2024/04/Proposed-Cancellation-of-Admission-to-Trading-07_00_13-02-Apr-2024-REDX-News-article-_-London-Stock-Exchange.pdf
Interesting dates if one is hoping to top up Sipps and Isa
Agree recent patient conference for melanoma.the presentation for recent trials was delivered by Prof Sarah Danson of Sheffield , that video of trial updates is yet to be released . Sarah is also an investigator on the Modi trial
what will the poster look like when the new improved melanoma vaccine with enhancement and prolonged patent look like ?
exciting times
Under google search for AACR “ cancer vaccines ready for prime time “
BioNtech press release
https://markets.businessinsider.com/news/stocks/biontech-to-present-clinical-data-updates-for-personalized-mrna-based-and-targeted-oncology-candidates-at-aacr-2024-1033150461
Https://markets.financialcontent.com/stocks/article/bizwire-2024-4-1-pharmajet-announces-scientific-advisory-boards-and-presentation-at-world-vaccine-congress-in-washington-on-april-1
* The Scientific Advisory Boards bring together renowned industry experts in infectious diseases and oncology to accelerate PharmaJet’s partnering strategy with vaccine and pharmaceutical companies.
* Presentation scheduled for April 1, 2024 at 2:00 PM ET in Room 202A at the Walter E. Washington Convention Center, Washington, D.C.
Https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm
wonder if anyone is there from Scancell before the congress at AACR
we know LD is speaking about the Modi and Scope and results of the trial
Form the twitter page OCTOBER 18TH 2023 ; this post has had 1,252Views;
·Our CEO Prof Lindy Durrant will be speaking at the World Vaccine Congress in Barcelona on Thursday 19th October at 11am about Scancell’s cancer vaccines SCIB1 and Modi-1.
#WVCEU #Cancervaccines #Immunooncology #Immunotherapy
·
To list on Nasdaq do you need a USA address?
Morning all heading in the right direction. Does anyone have the link to LD at AACR conference?
Https://www.news-medical.net/news/20240321/LungVax-vaccine-uses-DNA-technology-to-prevent-lung-cancer.aspx
re Tim Elliot
https://www.immunology.ox.ac.uk/about/team/tim-elliott
Rob do you mean this :
https://www.dailymail.co.uk/health/article-13224439/Cancer-vaccine-AI-trials-effective-lung-cancer.html